Core Insights - The animal health sector experienced a slight increase of 0.36% on November 6, with *ST Lvkang leading the gains [1] - The Shanghai Composite Index closed at 4007.76, up 0.97%, while the Shenzhen Component Index closed at 13452.42, up 1.73% [1] Stock Performance - *ST Lvkang (002868) closed at 30.25, with a rise of 5.00% and a trading volume of 32,200 hands, amounting to a transaction value of 96.94 million yuan [1] - Other notable stocks include: - KQ Bio (688526) at 16.07, up 0.69% [1] - Biological Shares (600201) at 10.35, up 0.68% with a transaction value of 153 million yuan [1] - Ruipu Biological (300119) at 20.46, up 0.20% [1] - Pulaike (603566) at 14.09, up 0.14% [1] Capital Flow - The animal health sector saw a net outflow of 17.47 million yuan from institutional investors, while retail investors contributed a net inflow of 8.89 million yuan [2] - The capital flow for individual stocks indicates: - *ST Lvkang had a net inflow of 7.56 million yuan from institutional investors [3] - KQ Bio experienced a net inflow of 4.84 million yuan [3] - Biological Shares had a net inflow of 2.64 million yuan [3]

Core Points - The company announced a joint investment with professional investment institutions to establish a partnership for investing in the pet industry chain [1] - The total subscribed capital of the partnership is RMB 406 million, with the company contributing RMB 154 million, accounting for 37.9310% of the total [1] - The partnership has been registered with the Asset Management Association of China and has obtained the Private Investment Fund Registration Certificate [1] Investment Details - The meeting to approve the investment was held on October 13, 2025 [1] - The partnership includes Tianjin Port Free Trade Zone Emerging Industry Development Fund Partnership, Tianjin Lingang Equity Investment Fund Management Co., Ltd., and Mingzhi Hexin (Tianjin) Equity Investment Fund Management Co., Ltd. [1] - The investment aims to target relevant projects within the pet industry [1]

证券代码：300119 证券简称：瑞普生物 公告编号：2025-090 瑞普生物股份有限公司 关于与专业投资机构共同投资合伙企业备案完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、对外投资概述 根据瑞普生物股份有限公司（以下简称"公司"）战略规划的需要，为进一 步拓展公司在宠物产业链布局，更好地借助专业机构力量及资源优势，提高公司 的综合竞争力。公司于 2025 年 10 月 13 日召开第五届董事会第二十八次（临时） 会议，审议通过了《关于与专业投资机构共同投资的议案》，同意公司与天津港 保税区新兴产业发展基金合伙企业（有限合伙）、天津临港股权投资基金管理有 限公司、明智合信（天津）股权投资基金管理有限公司共同投资设立天津保瑞股 权投资合伙企业（有限合伙）（以下简称"合伙企业"），用于投资宠物产业链 相关标的。合伙企业认缴出资总额为人民币 40,600 万元，其中，公司作为有限 合伙人以自有资金出资人民币 15,400 万元，占合伙企业认缴出资总额的 37.9310%。具体内容详见公司于 2025 年 10 月 14 日披露的《关于与专业投资 ...

Core Viewpoint - Reap Bio announced on November 4 that the total number of shareholders is expected to be approximately 25,000 by October 31, 2025 [2] Summary by Categories - **Company Information** - Reap Bio's total number of shareholders is projected to reach around 25,000 by October 31, 2025 [2]

Core Insights - The animal health sector experienced a decline of 0.35% on November 3, with Reap Bio leading the losses [1] - The Shanghai Composite Index closed at 3976.52, up 0.55%, while the Shenzhen Component Index closed at 13404.06, up 0.19% [1] Stock Performance Summary - Hai Li Biological (603718) closed at 7.02, up 2.03% with a trading volume of 101,600 shares and a turnover of 70.93 million yuan [1] - Shen Lian Biological (688098) closed at 11.36, up 1.43% with a trading volume of 133,100 shares and a turnover of 150 million yuan [1] - Yong Shun Biological (920729) closed at 10.09, up 1.00% with a trading volume of 23,800 shares and a turnover of 24.09 million yuan [1] - The worst performer was Reap Bio (300119), which closed at 21.01, down 2.51% with a trading volume of 103,300 shares and a turnover of 219 million yuan [2] Capital Flow Analysis - The animal health sector saw a net outflow of 35.26 million yuan from institutional investors, while retail investors had a net inflow of 26.79 million yuan [2] - The main capital inflow was observed in Shen Lian Biological, with a net inflow of 4.03 million yuan from institutional investors [3] - Conversely, Reap Bio experienced a net outflow of 1.29 million yuan from institutional investors [3]

Core Viewpoint - The stock price of Reap Bio fell by 2.09% on November 3, with a trading volume of 140 million yuan and a market capitalization of 9.806 billion yuan [1] Company Overview - Reap Bio, established on August 2, 2001, and listed on September 17, 2010, is located in the Tianjin Free Trade Zone. The company specializes in the research, production, and sales of veterinary biological products, chemical drugs, biological agents, traditional veterinary medicine, natural plant medicines, premixed feeds, feed additives, and veterinary raw materials [2] - The main business revenue composition is 77.95% from animal protection and 22.05% from the pet supply chain [2] - As of October 20, 2023, the number of shareholders is 25,000, with an average of 13,398 circulating shares per person [2] Financial Performance - For the period from January to September 2025, Reap Bio achieved a revenue of 2.544 billion yuan, representing a year-on-year growth of 45.66%. The net profit attributable to the parent company was 362 million yuan, with a year-on-year increase of 48.04% [2] - Since its A-share listing, Reap Bio has distributed a total of 1.371 billion yuan in dividends, with 462 million yuan distributed over the past three years [3] Shareholding Structure - As of September 30, 2025, the sixth largest circulating shareholder is the Guotai Zhongzheng Livestock Breeding ETF, holding 6.3383 million shares, an increase of 2.3571 million shares from the previous period. The Hong Kong Central Clearing Limited is the tenth largest shareholder, holding 3.6017 million shares, a decrease of 2.9711 million shares from the previous period [3]

Core Insights - The report maintains a positive outlook on the agricultural sector, particularly in pig farming, despite ongoing losses in the industry [1][3] - The report highlights a potential acceleration in capacity reduction due to supply pressures and policy guidance [6][19] Group 1: Pig Farming - The number of breeding sows decreased by 0.20% month-on-month in September, with a total of 40.35 million sows reported [20][21] - Pig prices have been on the rise, with the average price for market pigs reaching 12.22 CNY/kg on October 30, reflecting a week-on-week increase of 7.10% [29][30] - The profitability of pig farming remains negative, with losses of 89.33 CNY per head for self-bred pigs and 179.72 CNY per head for purchased piglets as of October 31 [35][37] Group 2: Poultry Farming - The average price for white feather broilers increased to 7.09 CNY/kg on October 31, marking a week-on-week rise of 3.05% [39][42] - The report notes a significant increase in the number of breeding stock, with a 143.18% month-on-month rise in the number of grandparent stock updated in October [39][40] Group 3: Animal Health - The demand for animal health products is expected to rebound, driven by a recovery in breeding cycles and an increase in livestock numbers [48] - The report mentions that several companies are actively developing new products, which may enhance growth prospects for the sector [48] Group 4: Seed Industry - The average prices for wheat, soybean meal, and corn have increased, with wheat and soybean meal rising by 0.9% and 1.3% respectively as of October 31 [52][53] - The report emphasizes the importance of food security and the promotion of biotechnology in the seed industry [52][56] Group 5: Pet Industry - Pet food exports amounted to 823 million CNY in September, showing a year-on-year decline of 6.8% [57][60] - Domestic sales of pet food have continued to grow, with a combined growth rate of 3% across major e-commerce platforms in September [60]

Investment Rating - The report maintains a "Buy" rating for the company, with a target price based on the last closing price of 21.35 [1] Core Insights - The company reported a revenue of 25.44 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 13.50%. The net profit attributable to shareholders reached 3.62 billion yuan, up 45.64% year-on-year. In the third quarter alone, revenue was 8.37 billion yuan, a 1.44% increase year-on-year, with a net profit of 1.06 billion yuan, reflecting a 23.02% year-on-year growth [4][5] - The traditional livestock and poultry health business continues to grow steadily, with an optimized product structure. The pet health segment is gradually building ecological advantages. The company is also actively expanding into the ruminant vaccine market through a joint venture with Shengwei Biological, focusing on the development and production of vaccines for cattle and sheep [5] - The company is entering the microbial protein industry, which is expected to contribute to new revenue streams. A project for the industrialization of microbial protein with a total investment of 679 million yuan is underway, with 296 million yuan raised for this purpose. This strategic move aims to extend the company's business from animal health to broader high-quality protein solutions [5] Financial Summary - The company is projected to achieve revenues of 35.29 billion yuan, 38.82 billion yuan, and 42.71 billion yuan for the years 2025, 2026, and 2027, respectively. The net profit attributable to shareholders is expected to be 4.74 billion yuan, 5.03 billion yuan, and 5.49 billion yuan for the same years. Corresponding price-to-earnings ratios (PE) are forecasted to be 22.27, 20.06, and 18.36 [6][7] - The financial indicators show a gross margin of 45.00% for 2025, with a net profit margin of 13.43%. The revenue growth rate is expected to be 14.97% for 2025, with a net profit growth rate of 57.64% [9]

Core Viewpoint - The company, Reap Bio (300119), is deeply engaged in the pet medicine sector, holding 18 new veterinary drug registration certificates to meet diverse medical needs in pet healthcare [1] Group 1: Product Development - The company focuses on developing key products such as pet vaccines and deworming medications, including advanced products like the cat quadrivalent mRNA vaccine and dog quadrivalent vaccine [1] - Ongoing research includes vaccines for feline infectious peritonitis and various internal medicine and deworming drugs, indicating a strong pipeline of innovative products [1] Group 2: Ecosystem and Collaboration - The company aims to build a comprehensive pet health ecosystem through deep collaboration among its three strategic segments: Reap Bio, Ruipai Pet Hospital, and Zhongrui Supply Chain [1] - This collaboration creates a complete value chain that spans "research - validation - distribution - service," enhancing the overall effectiveness of the company's offerings [1] Group 3: Innovation and Market Strategy - Reap Bio constructs a technological moat through innovative products and continuous breakthroughs in technical barriers, supported by a network of over 10,000 terminals [1] - The company emphasizes a feedback loop of "clinical validation - demand response - precise research and development" to drive innovation [1] - Zhongrui Supply Chain is positioned as a global channel engine, connecting the production, distribution, and consumption ends of the market [1]

Group 1 - The Tianjin Free Trade Zone concept declined by 2.70%, ranking among the top declines in the concept sector, with companies like Saixiang Technology hitting the limit down [1] - Major stocks within the Tianjin Free Trade Zone concept that experienced significant declines include HNA Technology, Jintou City Development, and Bohai Chemical [1] - The net outflow of main funds from the Tianjin Free Trade Zone concept reached 276 million yuan, with 11 stocks experiencing net outflows, and 5 stocks seeing outflows exceeding 10 million yuan [2] Group 2 - HNA Technology had the largest net outflow of main funds at 113 million yuan, followed by Saixiang Technology and Jiuan Medical with net outflows of 107 million yuan and 2.52 million yuan respectively [2] - The stocks with the highest net inflows included Youfa Group, Tianjin Port, and Haitai Development, with inflows of 19.56 million yuan, 11.50 million yuan, and 5.79 million yuan respectively [3] - The trading performance of key stocks in the Tianjin Free Trade Zone concept showed significant volatility, with Saixiang Technology down by 10% and HNA Technology down by 5.92% [2][3]